Bio-Path (BPTH) Competitors $0.16 +0.02 (+10.00%) As of 04/17/2025 03:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BPTH vs. SXTP, ADIL, NCNA, CPHI, CANF, PWUP, MBIO, ONCO, ATNF, and DRMAShould you be buying Bio-Path stock or one of its competitors? The main competitors of Bio-Path include 60 Degrees Pharmaceuticals (SXTP), Adial Pharmaceuticals (ADIL), NuCana (NCNA), China Pharma (CPHI), Can-Fite BioPharma (CANF), PowerUp Acquisition (PWUP), Mustang Bio (MBIO), Onconetix (ONCO), 180 Life Sciences (ATNF), and Dermata Therapeutics (DRMA). These companies are all part of the "pharmaceutical products" industry. Bio-Path vs. 60 Degrees Pharmaceuticals Adial Pharmaceuticals NuCana China Pharma Can-Fite BioPharma PowerUp Acquisition Mustang Bio Onconetix 180 Life Sciences Dermata Therapeutics 60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking. Does the media favor SXTP or BPTH? In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Bio-Path. 60 Degrees Pharmaceuticals' average media sentiment score of 1.00 beat Bio-Path's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment 60 Degrees Pharmaceuticals Positive Bio-Path Neutral Which has more volatility and risk, SXTP or BPTH? 60 Degrees Pharmaceuticals has a beta of 3.41, suggesting that its stock price is 241% more volatile than the S&P 500. Comparatively, Bio-Path has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Do analysts rate SXTP or BPTH? Bio-Path has a consensus price target of $20.00, indicating a potential upside of 12,021.21%. Given Bio-Path's stronger consensus rating and higher possible upside, analysts clearly believe Bio-Path is more favorable than 60 Degrees Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 60 Degrees Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Bio-Path 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, SXTP or BPTH? 60 Degrees Pharmaceuticals has higher revenue and earnings than Bio-Path. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio60 Degrees Pharmaceuticals$607.57K7.66-$3.77M-$50.41-0.06Bio-PathN/AN/A-$16.08MN/AN/A Does the MarketBeat Community favor SXTP or BPTH? Bio-Path received 281 more outperform votes than 60 Degrees Pharmaceuticals when rated by MarketBeat users. Likewise, 52.71% of users gave Bio-Path an outperform vote while only 5.26% of users gave 60 Degrees Pharmaceuticals an outperform vote. CompanyUnderperformOutperform60 Degrees PharmaceuticalsOutperform Votes15.26%Underperform Votes1894.74% Bio-PathOutperform Votes28252.71% Underperform Votes25347.29% Do insiders & institutionals believe in SXTP or BPTH? 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 10.3% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is SXTP or BPTH more profitable? 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets 60 Degrees PharmaceuticalsN/A N/A -113.43% Bio-Path N/A -2,842.40%-337.48% Summary60 Degrees Pharmaceuticals beats Bio-Path on 9 of the 14 factors compared between the two stocks. Get Bio-Path News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTH vs. The Competition Export to ExcelMetricBio-PathPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.37M$6.46B$5.31B$7.35BDividend YieldN/A3.22%5.47%4.31%P/E RatioN/A6.9521.9417.82Price / SalesN/A231.01380.9497.72Price / CashN/A65.6738.3134.64Price / Book0.235.936.453.98Net Income-$16.08M$143.22M$3.22B$247.81M7 Day Performance15.55%4.28%5.85%3.19%1 Month Performance-5.17%-13.11%-9.58%-7.70%1 Year Performance-96.15%-8.51%11.85%1.49% Bio-Path Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTHBio-Path1.3615 of 5 stars$0.17+10.0%$20.00+12,021.2%-96.2%$1.37MN/A0.0010Analyst ForecastGap DownSXTP60 Degrees Pharmaceuticals1.2811 of 5 stars$3.26+10.1%N/A+162.2%$4.80M$607,574.00-0.323Short Interest ↓ADILAdial Pharmaceuticals2.4895 of 5 stars$0.72+2.1%$8.00+1,003.8%-64.5%$4.77MN/A-0.2220Positive NewsNCNANuCana2.6408 of 5 stars$0.83+10.6%$25.00+2,913.5%-77.2%$4.71MN/A-0.0830Positive NewsCPHIChina PharmaN/A$0.14-0.8%N/A-95.3%$4.61M$4.53M0.00250Analyst ForecastNews CoverageCANFCan-Fite BioPharma2.1354 of 5 stars$1.30-17.2%$14.00+976.9%-39.1%$4.60M$667,000.00-0.738Analyst ForecastNews CoverageGap UpHigh Trading VolumePWUPPowerUp AcquisitionN/A$0.59+11.3%N/A-94.9%$4.58MN/A0.00N/AGap UpHigh Trading VolumeMBIOMustang Bio1.6961 of 5 stars$1.36-2.2%$100.00+7,252.9%-92.2%$4.50MN/A-0.02100Short Interest ↑Positive NewsONCOOnconetix1.1021 of 5 stars$0.07+11.7%N/A-98.8%$4.49M$1.87M0.0012Short Interest ↓ATNF180 Life SciencesN/A$0.85+0.3%N/A-50.6%$4.42MN/A0.007DRMADermata Therapeutics1.8719 of 5 stars$0.81+0.2%$6.00+641.2%-85.3%$4.40MN/A-0.058Short Interest ↑News CoveragePositive News Related Companies and Tools Related Companies SXTP Alternatives ADIL Alternatives NCNA Alternatives CPHI Alternatives CANF Alternatives PWUP Alternatives MBIO Alternatives ONCO Alternatives ATNF Alternatives DRMA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTH) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bio-Path With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BPTH Stock Free BPTH Stock Alerts